Home
Projects
Labs
Publications
Teaching
Events
Press
Collaborators
Job Openings
Light
Dark
Automatic
Christoph Buhl
Latest
Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.
Cite
×